Factor XI inhibition in hemodialysis patients: the safer anticoagulation?
Kidney Int
; 106(1): 21-23, 2024 Jul.
Article
em En
| MEDLINE
| ID: mdl-38906653
ABSTRACT
Chronic hemodialysis patients exhibit an excessive cardiovascular risk and a marked increase in both thromboembolism and bleeding episodes. Factor XI inhibition may provide anticoagulation, with a low risk of bleeding, and several factor XI inhibitors, including fesomersen, an antisense oligonucleotide, are under development. Recently, a phase 2 study of fesomersen showed a good safety profile in chronic hemodialysis patients and suggested that clotting rates of the arteriovenous fistula and the dialysis circuit are lower.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fator XI
/
Diálise Renal
/
Hemorragia
/
Anticoagulantes
Limite:
Humans
Idioma:
En
Revista:
Kidney Int
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Alemanha